Drug Interactions with Cannabis
Medicinal cannabis use is at an all-time high in the United States. From 2016 to 2020 alone, the number of patients enrolled in a state medical marijuana program quadrupled, according…
Author Archive for: Nikhil
Entries by Nikhil Jain
Embracing a New Era: The Impact of Rescheduling Cannabis on Public Health and Clinical Research
As the DEA proposes moving cannabis to Schedule III of the Controlled Substances Act, we enter a transformative period in the understanding and utilization of this complex botanical product. Moving…
Rescheduling Cannabis in America: Celebration or disappointment? It is in the eye of the beholder.
On April 30th, 2024, the DEA accepted the recommendation of the U.S. Health and Human Services and FDA that cannabis should be reclassified as a Schedule 3 drug along with…
Job Opportunity: Cannabis Ombudsperson for the State of Connecticut
The State of Connecticut, Office of the Healthcare Advocate (OHA) is recruiting for a Cannabis Ombudsperson position in Hartford, CT. They are seeking a professional who is familiar with the…
Board Member at Asia International Hemp Forum
Dr. Shiksha Gallow, one of the Board members of the SCC, was invited as one of the global keynote speakers at the Asia International Hemp and Cannabis Forum in Bangkok,…
Does Cannabis Cause Heart Failure and Stroke?
Does Cannabis Cause Heart Failure and Stroke? You may have seen the recent headlines about two new studies that found “marijuana use raises risk of heart attack, heart failure and…
Middle School Cannabis Curriculum
SCC Member, Dave Gordon MD, was recently invited to review a middle school cannabis curriculum. Read below to see how education for this population has evolved since the DARE Program days.
Medical Cannabis Science & Therapeutics Masters Program Commencement Ceremony
It is with great honor and pride that we share that our SCC Board Member, Dr. Patricia Frye, on the 17th of May 2023, gave the Commencement Ceremony to the…
Rapid treatments for depression: Endocannabinoid system as a therapeutic target
Current first-line treatments for major depressive disorder (MDD), i.e., antidepressant drugs and psychotherapy, show delayed onset of therapeutic effect as late as 2–3 weeks or more. In the clinic, the speed of beginning of the actions of antidepressant drugs or other interventions is vital for many reasons.
Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics
Preclinical models provided ample evidence that cannabinoids are cytotoxic against cancer cells. Among the best studied phytocannabinoids, cannabidiol (CBD) is most promising for the treatment of cancer as it lacks the psychotomimetic properties of delta-9-tetrahydrocannabinol (THC).
Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial
Cannabidiol (CBD) has demonstrated anti-inflammatory, analgesic, anxiolytic and neuroprotective effects that have the potential to benefit athletes. This pilot study investigated the effects of acute, oral CBD treatment on physiological and psychological responses to aerobic exercise to determine its practical utility within the sporting context.
Marijuana and Myocardial Infarction in the UK Biobank Cohort
Atrial fibrillation, ventricular tachycardia, acute coronary syndromes, and cardiac arrest have been attributed to marijuana. But the National Academy of Science’s 2017 Report, The Health Effects of Cannabis and Cannabinoids, found limited evidence that acute marijuana smoking is positively associated with an increased risk of acute myocardial infarction, and uncovered no evidence to support or refute associations between any chronic effects of marijuana use and increased risk of myocardial infarct (MI).